Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.8 GBX | 0.00% | -6.91% | +41.44% |
May. 01 | Poolbeg Pharma Secures Full Patent in US for Immunomodulator II | MT |
May. 01 | Poolbeg Pharma celebrates full patent approval for Immunomodulator II | AN |
Sales 2023 | - | Sales 2024 * | - | Capitalization | 64M 81.28M |
---|---|---|---|---|---|
Net income 2023 | -3M -3.81M | Net income 2024 * | -6M -7.62M | EV / Sales 2023 | - |
Net cash position 2023 * | 10.77M 13.68M | Net cash position 2024 * | 6.2M 7.87M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-11.5
x | P/E ratio 2024 * |
-9.85
x | Employees | 12 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.34% |
1 week | -6.91% | ||
Current month | +6.22% | ||
1 month | +28.64% | ||
3 months | +12.28% | ||
6 months | +37.63% | ||
Current year | +41.44% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 21-04-30 | |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Carol Dalton
IRC | Investor Relations Contact | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Luke O'Neill
BRD | Director/Board Member | 60 | - |
Chief Executive Officer | 53 | 21-04-30 | |
Cathal Friel
FOU | Founder | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 12.8 | 0.00% | 875,875 |
24-05-16 | 12.8 | -2.66% | 2,084,249 |
24-05-15 | 13.15 | -2.95% | 692,157 |
24-05-14 | 13.55 | 0.00% | 439,570 |
24-05-13 | 13.55 | -1.45% | 2,015,339 |
Delayed Quote London S.E., May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.44% | 81.32M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- POLB Stock